Eptinezumab, our solely owned lead investigational product candidate, is a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand. CGRP is a small protein and a validated biological target that is understood to drive migraine initiation, maintenance and chronification. Eptinezumab was discovered by Alder scientists and is the result of a deliberate process coupled with proprietary technologies to design a monoclonal antibody inhibiting CGRP that delivers a competitively differentiated profile and a unique clinical benefit to patients. We believe eptinezumab holds the potential to be a transformative therapeutic and meet a profound medical need, changing the migraine prevention treatment paradigm for physicians and patients living with migraine. On February 21, 2019, we submitted a BLA to the FDA for eptinezumab for the prevention of migraine. Eptinezumab has been successfully evaluated in multiple clinical trials including two Phase 3 clinical trials, PROMISE 1 and PROMISE 2. Our clinical data
Company profile
Ticker
ALDR
Exchange
Website
CEO
Robert W. Azelby
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
ALDR stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
1 Nov 19
POSASR
Automatic shelf registration (post-effective amendment)
22 Oct 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Oct 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Oct 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Oct 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Oct 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Oct 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Oct 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Oct 19
25-NSE
Exchange delisting
22 Oct 19
Latest ownership filings
SC 13G/A
Beneficial ownership report (amended)
13 Feb 20
SC 13G
Beneficial ownership report
31 Oct 19
SC 13D/A
Alder Biopharmaceuticals Inc
25 Oct 19
4
Carlos Campoy
24 Oct 19
4
PAUL STRECK
24 Oct 19
4
Nadia Dac
24 Oct 19
4
Jeremy Green
24 Oct 19
4
Erin Lavelle
24 Oct 19
4
James B Bucher
24 Oct 19
4
Randal Hassler
24 Oct 19
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|